News
ACHFF
0.735
+4.11%
0.029
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
Barchart · 08/11 06:44
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Barchart · 06/04 06:41
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Barchart · 05/22 05:50
Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD
TipRanks · 02/09 12:45
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Barchart · 02/09 06:28
Arch granted ethics approval for St. Michaels participation in Phase II trial
TipRanks · 12/16/2025 12:45
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Barchart · 12/16/2025 06:40
Arch biopartners launches non-brokered private placement
Seeking Alpha · 11/10/2025 14:16
Arch Biopartners Arranges Non-Brokered Private Placement
Barchart · 11/10/2025 07:10
Weekly Report: what happened at ACHFF last week (0908-0912)?
Weekly Report · 09/15/2025 10:35
Weekly Report: what happened at ACHFF last week (0901-0905)?
Weekly Report · 09/08/2025 10:37
Weekly Report: what happened at ACHFF last week (0825-0829)?
Weekly Report · 09/01/2025 10:33
Weekly Report: what happened at ACHFF last week (0818-0822)?
Weekly Report · 08/25/2025 10:40
More
Webull provides a variety of real-time ACHFF stock news. You can receive the latest news about Arch Biopartners through multiple platforms. This information may help you make smarter investment decisions.
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.